Go To Global Site
Welcome to UCB in the United States
Victor_BTS_1280x960

Apr

25

UCB’s Dr. Victor Sloan Shares His Commitment to Go Boldly

Dr. Victor Sloan, UCB’s VP & Development Strategy Lead (immunology), was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign. Learn more about Dr. Sloan’s work and his motivation to find groundbreaking solutions.

Research_for_blog_post_4.20.18_1280x960

Apr

20

UCB’s Commitment in Neurology

Today, we announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),1 an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

blog_announcement_crop_002

Apr

20

Press Release: UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

bigger-Parkinsons-Stat-with-Logo--source-NEW-WITH-LOGO

Apr

19

UCB Celebrates Parkinson’s Disease Awareness Month

April is Parkinson’s Awareness Month. To honor those living with Parkinson’s disease (PD), we’re spreading awareness about the disease and sharing some of our favorite stories of inspiration.

Blog_Photo_1280x960

Apr

16

Welcome to UCB USA

As the U.S. affiliate of UCB, a global biopharmaceutical company, we are excited to be relaunching UCB-USA.com and a blog with news on UCB in the U.S.

UCB_campus_1280x960

Apr

13

UCBCares is Dedicated to Providing Caring Experiences

UCBCares® is UCB, Inc.'s single source solution center in the U.S. dedicated to providing exceptional caring experiences and solutions for all incoming inquiries to UCB from patients, caregivers, and healthcare providers.

446_LaboPics-HR.jpg_1280x960

Apr

05

Press Release: UCB strengthens research capabilities with acquisition

UCB strengthens research capabilities with acquisition of Element Genomics, a Duke University biotech spin-off